Regeneron Pharmaceuticals, Inc.’s stock price plummets to $490.28, marking a significant 19.01% drop

Regeneron Pharmaceuticals, Inc. (REGN)

490.28 USD -115.11 (-19.01%) Volume: 6.31M

Regeneron Pharmaceuticals, Inc.’s stock price takes a hit, plunging to 490.28 USD, a significant -19.01% downturn in today’s trading session with a high trading volume of 6.31M shares, reflecting a substantial YTD decrease of -31.17%, indicating a tumultuous year for REGN investors.

Latest developments on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. stock price experienced fluctuations today following the release of mixed trial data on a smoker’s lung drug co-developed with Sanofi. The drug, itepekimab, showed uneven results in key trials, causing a dip in both Regeneron and Sanofi stock. Additionally, news broke that Regeneron would be acquiring bankrupt genetic testing company 23andMe for $256 million, leading to further investor speculation and market movements. Amidst these events, various asset management firms made significant investments in Regeneron, indicating continued interest in the pharmaceutical company’s future prospects.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma